checkAd

electroCore Announces 510(k) Clearance of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

Nachrichtenquelle: globenewswire
16.02.2021, 14:00  |  105   |   |   

FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age

ROCKAWAY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on Friday, February 12, 2021, the company received Section 510(k) clearance from the Unites States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. gammaCore is now cleared for most forms of primary headache including the acute and preventive treatment of migraine in adolescents and adults, as well as the acute and preventive treatment of cluster headache in adults.

Dr. Andrew Hershey, Endowed Chair and Director of Neurology at Cincinnati Children’s Medical Center and Professor of Pediatrics and Neurology at the University of Cincinnati College of Medicine, commented, “Migraine is a very common disease in adolescents that can affect them at home, school and socially. gammaCore, which can be used acutely to treat migraine attacks, or when used daily can decrease the number of attacks, is an exciting treatment that I look forward to offering to my adolescent patients.”

It is estimated that 10% of all school age children and up to 28% of teens between the ages of 15-19 live with migraine1, while 37% of children find their schoolwork suffers during a headache which can negatively affect a teen's social life.2 

“gammaCore (nVNS) is the only treatment option, drug or device, that is currently available for the acute and preventive treatment of migraine in adolescents,” said Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “With their interest in technology and desire to avoid prescription drugs, gammaCore represents a unique treatment for adolescents with migraine. We would like to thank the Division of Neuromodulation and Physical Medicine Devices and their colleagues at the FDA for their efforts to review and clear the expanded label for gammaCore."

The label expansion was based on previously reported randomized controlled trials of gammaCore for the acute and preventive treatment of migraine, and was supported by a small study (n=9) in adolescents where 46.8% of all treated attacks were successfully resolved without the use of any acute rescue medication.3

Seite 1 von 4
electroCore Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

electroCore Announces 510(k) Clearance of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of ageROCKAWAY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel